Amgen vs Pfizer
AMGN and PFE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMGN and PFE compare
Amgen is the larger company, worth 1.5 times as much as Pfizer ($252B against $164B).
On earnings, Amgen is cheaper: it trades at 27.0× trailing earnings, against 41.2× for Pfizer.
Amgen grew revenue faster over the last twelve months (8.2% versus 1.3% for Pfizer).
Amgen keeps more of each dollar of sales as profit, with a net margin of 24.1% compared with 6.3% at Pfizer.
Both pay dividends: Amgen yields 2.1% and Pfizer 4.5%.
Amgen scores higher on the StockData Score (17 against 8 for Pfizer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMGN | PFE |
|---|---|---|
| Size and price | ||
| Market cap | $252B | $164B |
| Share price | $465.67 | $28.83 |
| Change, 1 year | 38.5% | 13.0% |
| Change, 5 years | 126% | −43.2% |
| Beta (5Y) | 0.41 | 0.44 |
| Employees | 32K | 75K |
| StockData Score | ||
| Total score | 17 (better) | 8 |
| Valuation score | 0 | 1 (better) |
| Growth score | 5 (better) | 0 |
| Performance score | 6 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 27.0× (better) | 41.2× |
| P/S | 6.5× | 2.6× (better) |
| P/B | 17.5× | 1.8× (better) |
| EV/EBITDA | 19.1× | 16.1× (better) |
| P/FCF | 26.3× | 13.9× (better) |
| PEG | 4.89 | – |
| FCF yield | 3.8% | 7.2% (better) |
| Fair value | $380.41 | $20.06 |
| Margin of safety | −22.4% (better) | −43.7% |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | 1.3% |
| Revenue growth, 5Y average | 7.6% | 8.5% (better) |
| Net income growth (TTM) | 34.1% (better) | −59.0% |
| EPS growth (TTM) | 33.3% (better) | −59.3% |
| EPS growth, 5Y average | 2.9% (better) | −3.6% |
| Profitability | ||
| Gross margin | 70.9% | 73.4% (better) |
| Operating margin | 32.4% | – |
| Net margin | 24.1% (better) | 6.3% |
| FCF margin | 24.6% (better) | 18.5% |
| Return on equity | 78.4% (better) | 4.4% |
| Return on invested capital | 19.5% | – |
| Financial health | ||
| Debt / equity | 3.76 | 0.70 (better) |
| Net debt / EBITDA | 2.67 (better) | 3.84 |
| Interest coverage | 4.8× | – |
| Current ratio | 1.48 (better) | 1.42 |
| Altman Z-score | 2.54 (better) | 2.03 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | 4.5% (better) |
| Payout ratio | 57.1% | – |
| Years of dividend growth | 9 | 15 (better) |
| Dividend growth, 5Y average | 8.0% (better) | 2.4% |
| Shareholder yield | 2.1% | 4.5% (better) |
| Ownership | ||
| Held by institutions | 82.7% | 67.2% |
| Held by insiders | 0.21% | 0.03% |
| Insider net buying, 12 months | −$25.7M | $2.8M (better) |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 2.3% | 2.4% |
Go deeper
- AMGN stock overview
- AMGN income statement
- AMGN valuation and score
- PFE stock overview
- PFE income statement
- PFE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.